Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology

Endocrinology

Volumn 147, Issue 10, 2006, Pages 4561-4568

  Gilbert, Jacqueline A ^a   Kalled, Susan L ^b   Moorhead, Jane ^c   Hess, Donna M ^b   Rennert, Paul ^b   Li, Zhifang ^b   Khan, M Zareen ^c   Banga, J Paul ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BIOGEN   (United States)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; B LYMPHOCYTE ANTIGEN; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; LIGAND; SYNDECAN 1; THYROID STIMULATING IMMUNOGLOBULIN; THYROXINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAVES DISEASE; HISTOPATHOLOGY; HYPERTHYROIDISM; LYMPHOID ORGAN; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN;

ADENOVIRIDAE; ANIMALS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; DIPHENYLAMINE; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; GRAVES DISEASE; IMMUNOGLOBULINS, THYROID-STIMULATING; IMMUNOHISTOCHEMISTRY; LIGANDS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; RECEPTORS, THYROTROPIN; THYROIDITIS, AUTOIMMUNE; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748746856     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0507     Document Type: Article

References (45)

1. Jacobson DL, Gange SJ, Rose NR, Graham NMH 1997 Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84:223-243
2. Rees Smith B, McLachlan SM, Furmaniak J 1988 Autoantibodies to the thyrotropin receptor. Endocr Rev 9:106-121
3. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM 1998 The thyrotropin (TSH) releasing hormone receptor: interaction with TSH and autoantibodies. Endocr Rev 19:673-716
4. Cooper DS 2003 Hyperthyroidism. Lancet 362:459-468
5. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P 1999 Cancer incidence and mortality after radioiodine treatment for hyperthyroidism.: a population-based cohort study. Lancet 353:2111-2115
6. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ 2003 Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 170:6348-6354
7. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE 1998 Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 83:998-1004
8. Bahn RS 2003 Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 88:1939-1946
9. Williams RC, Marshall NJ, Kilpatrick K, Montano J, Brickell PM, Goodhall M, Ealey PA, Shine B, Weetman AP, Craig RK 1988 κ/λ Immunoglobulin distribution in Graves' thyroid stimulating antibodies. Simultaneous analysis of Cλ gene polymorphisms. J Clin Invest 82:1306-1312
10. Weetman AP, Yateman ME, Ealey PA, Black CM, Reimer CB, Williams RC, Shine B, Marshall NJ 1990 Thyroid stimulating antibody activity between different immunoglobulin G subclasses. J Clin Invest 86:723-727
11. Mackay F, Kalled SL 2002 TNF ligands and receptor in autoimmunity: an update. Curr Opin Immunol 14:783-790
12. Mackay F, Schneider P, Rennert P, Browning J 2003 BAFF and APRIL: a tutorial in B cell survival. Ann Rev Immunol 21:231-264
13. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL 1999 Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697-1710
14. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F 2002 Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 109:59-68
15. Kalled SL, Ambrose C, Hsu YM 2004. The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun 8:206-242
16. Yang M, Hase H, Legarda-Addison D, Varughese L, Seed B, Ting AT 2005 B cell maturation antigen, the receptor for a proliferating-inducing ligand and B cell activating factor of TNF family, induces antigen presentation in B cells. J Immunol 175:2814-2824
17. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ 2004 BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199:91-98
18. Castigli E, Scott S, Dedeoglu F, Jabara H, Bhan AK, Mizoguchi E, Geha RS 2004 Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 101:3903-3908
19. Varfolomeev E, Kischkel F, Martin F, Seshasayee D, Wang H, Lawrence D, Olsson C, Tom L, Ericson S, French D, Schow P, Grewal IS, Ashkenazi A 2004 APRIL-deficient mice have normal immune system development. Mol Cell Biol 24:977-1006
20. Day ES, Cachero TG, Qian F, Sun Y, Wen D, Pelletier M, Hsu YM, Whitty A 2005 Selectivity of BAFF/BlyS and APRIL for binding to the TNF-family receptors BAFFR/BR3 and BCMA. Biochemistry 44:1919-1931
21. Patel DR, Wallweber HJA, Yin JP, Shriver SK, Marsters SA, Gordon NC, Starovasnik MA, Kelley RF 2004 Engineering an APRIL-specific B cell maturation antigen. J Biol Chem 279:16727-16735
22. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH 2000 TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995-999
23. Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Ashkenazi A, Grewal IS 2001 TACI-ligand interactions are required for T cell activation and collagen induced arthritis in mice. Nat Immunol 2:632-637
24. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH 2001 TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease, impaired B cell maturation in mice lacking BLyS. Immunity 15:289-302
25. Kalled SL 2005 The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 204:43-54
26. Kalled SL, Ambrose C, Hsu YM 2003 BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders. Expert Opin Ther Targets 7:115-123
27. Dillon SR, Gross JA, Ansell SM, Novak AJ 2006 An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5:235-246
28. Dogan RE, Vasu C, Holterman MJ, Prabhakar BS 2003 Absence of IL4, and not suppression of Th2 response, prevents development of experimental autoimmune Graves' disease. J Immunol 170:2195-2204
29. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, Mclachlan SM, Rapoport B 2003 Prevention of autoantibody-mediated Graves' like hyperthyroidism in mice with IL4, a Th2 cytokine. J Immunol 170:3522-3527
30. Nagayama Y, Watanabe K, Niwa M, Mclachlan SM, Rapoport B 2003 Schistosoma mansoni and α-galactosylceramide: prophylactic effect of Th1 immune suppression in a mouse model of Graves' hyperthyroidism. J Immunol 173:2167-2173
31. Nagayama Y, Saitoh O, McLachlan SM, Rapoport B, Kano H, Kumazawa Y 2004 TSH receptor-adenovirus-induced Graves' hyperthyroidism is attenuated in both interferon-gamma and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm. Clin Exp Immunol 138:417-422
32. Saitoh O, Mizutori Y, Takamura N, Yamasaki H, Kita A, Kuwahara H, Nagayama Y 2005 Adenovirus-mediated gene delivery of interleukin-10, but not transforming growth factor β, ameliorates the induction of Graves' hyperthyroidism in BALB/c mice. Clin Exp Immunol 141:405-411
33. Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, Mclachlan SM 2003 The thyrotropin receptor autoantigen in Graves' disease is the culprit as well as the victim. J Clin Invest 111:1897-1904
34. Chen CR, Pichurin P, Chazenbalk GD, Aliesky H, Nagayama Y, Mclachlan SM, Rapoport B 2004 Low dose immunization with adenovirus expressing the thyroid stimulating hormone receptor A-subunit deviates the antibody response toward that of autoantibodies in human Graves' disease. Endocrinology 145:228-233
35. Rao PV, Watson PF, Weetman AP, Carayanniotis G, Banga JP 2003 Contrasting activities of thyrotropin receptor antibodies in experimental models of Graves' disease induced by injection of transfected fibroblasts or deoxyribonucleic acid vaccination. Endocrinology 144:260-266
36. Pelletier M, Thompson JS, Qian F, Bixler SA, Gong D, Cachero T, Gilbride K, Day E, Zafari M, Benjamin C, Gorelik L, Whitty A, Kalled SL, Ambrose C, Hsu YM 2003 Comparison of soluble decoy IgG fusion proteins of BAFFR and BCMA as antagonists for BAFF. J Biol Chem 278:33127-33133
37. Thompson JS, Schneider P, Kalled SL, Wang L, Levevre EA, Cachero TG, Mackay F, Bixler SA, Zafari M, Liu ZY, Woodcock SA, Qian F, Batten M, Madry C, Richard Y, Benjamin CD, Browning JL, Tsapis A, Tschopp J, Ambrose C 2000 BAFF binds to the tumour necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 192:129-135
38. Stohl W 2005 BlySfulness does not equal Blissfulness in systemic lupus erythematosus: a therapeutic role for BlyS antagonists. Curr Dir Autoimmun 8:289-304
39. Sutherland APR, Ng LG, Fletcher CA, Shum B, Newton RA, Grey ST, Rolph MS, Mackay F, Mackay CR 2005 BAFF augments certain Th1-associated inflammatory responses. J Immunol 174:5537-5544
40. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, Qiang F, Gorelik L, Kalled SL, Acha-Orbea H, Rennert PD, Tschopp J, Schneider P 2005 Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201:1375-1383
41. Jacobi AM, Diamond B 2005 Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus. J Exp Med 202:341-344
42. Segundo C, Rodriguez C, Garcia-Poley A, Aguilar M, Gavilan I, Bellas C, Brieva JA 2001 Thyroid-infiltrating B lymphocytes in Graves' disease are related to marginal zone and memory B cell compartments. Thyroid 11:525-530
43. Paschke R, Vogg M, Swillens S, Usadel KH 1993 Correlation of microsomal antibodies with the intensity of the intrathyroidal autoimmune process in Graves' disease. J Clin Endocrinol Metab 77:939-943
44. Armengol MP, Juan M, Lucas-Martin A, Fernandez-Figueras MT, Jaraquemada D, Gallart T, Pujol-Borrell R 2001 Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol 159:861-873
45. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K 2005 Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol 25:189-201